FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE (bortezomib) for Injection

Sep 18, 2009 - Millennium: The Takeda Oncology Company today announced that the U.S. FDA has granted priority review to the Company's supplemental new drug application (sNDA) for VELCADE.

The details can be read here.